How have CHRO shares performed in 2024?

Chromocell Therapeutics' stock was trading at $4.80 at the beginning of 2024. Since then, CHRO shares have decreased by 66.7% and is now trading at $1.60. View the best growth stocks for 2024 here .

When did Chromocell Therapeutics IPO?

Chromocell Therapeutics (CHRO) raised $7 million in an initial public offering (IPO) on Friday, February 16th 2024. The company issued 1,100,000 shares at $6.00 per share.

When did the company's quiet period expire?

Chromocell Therapeutics' quiet period expired on Wednesday, March 27th. Chromocell Therapeutics had issued 1,100,000 shares in its public offering on February 16th. The total size of the offering was $6,600,000 based on an initial share price of $6.00. During the company's quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Chromocell Therapeutics?

Shares of CHRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:CHRO

Chromocell Therapeutics (CHRO) Stock Price, News & Analysis

→ A new way to collect income from stocks (From DTI) (Ad)

Free CHRO Stock Alerts

$1.60

+0.10 (+6.67%)

(As of 04/26/2024 ET)

Compare

Today's Range: $1.47
▼
$1.78
50-Day Range: $1.23
▼
$4.80
52-Week Range: $1.21
▼
$6.00

Volume: 26,703 shs
Average Volume: 22,654 shs
Market Capitalization: $9.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Social Media

Get Chromocell Therapeutics alerts:

Ad Colonial Metals

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

About Chromocell Therapeutics

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

CHRO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CHRO Stock News Headlines

April 9, 2024 | globenewswire.com

Chromocell Issues Letter to Stockholders from Chief Executive Officer

March 21, 2024 | globenewswire.com

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

April 28, 2024 | Colonial Metals (Ad)

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

March 18, 2024 | globenewswire.com

Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

March 11, 2024 | globenewswire.com

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

February 27, 2024 | globenewswire.com

Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions

February 21, 2024 | globenewswire.com

Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million

February 16, 2024 | globenewswire.com

Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

See More Headlines

Receive CHRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chromocell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/27/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSE:CHRO
CUSIP: N/A
CIK: 1919246
Web: chromocell.com
Phone: 732-514-2636
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 5,878,000
Free Float: N/A
Market Cap: $9.40 million
Optionable: N/A
Beta: N/A

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Francis Knuettel II (Age 58)
M.B.A., CEO, CFO, Treasurer & Secretary
Comp: $100k
Dr. Eric Lang M.D. (Age 61)
Chief Medical Officer
Comp: $264.99k

Key Competitors

View All Competitors

CHRO Stock Analysis - Frequently Asked Questions

How have CHRO shares performed in 2024?: Chromocell Therapeutics' stock was trading at $4.80 at the beginning of 2024. Since then, CHRO shares have decreased by 66.7% and is now trading at $1.60.
View the best growth stocks for 2024 here.
When did Chromocell Therapeutics IPO?: Chromocell Therapeutics (CHRO) raised $7 million in an initial public offering (IPO) on Friday, February 16th 2024. The company issued 1,100,000 shares at $6.00 per share.
When did the company's quiet period expire?: Chromocell Therapeutics' quiet period expired on Wednesday, March 27th. Chromocell Therapeutics had issued 1,100,000 shares in its public offering on February 16th. The total size of the offering was $6,600,000 based on an initial share price of $6.00. During the company's quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
How do I buy shares of Chromocell Therapeutics?: Shares of CHRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CHRO) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial